2020
DOI: 10.1097/aci.0000000000000706
|View full text |Cite
|
Sign up to set email alerts
|

Novel vaccines for allergen-specific immunotherapy

Abstract: Purpose of review Allergen-specific immunotherapy (AIT) is a highly economic, effective and disease-modifying form of allergy treatment but requires accurate prescription and monitoring. New molecular approaches are currently under development to improve AIT by reducing treatment-related side effects, cumbersome protocols and patients’ compliance. We review the current advances regarding refined diagnosis for prescription and monitoring of AIT and the development of novel molecular vaccines for AIT… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
10
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 17 publications
(11 citation statements)
references
References 94 publications
1
10
0
Order By: Relevance
“…They induce a regulatory response mediated by IL-35 and IL-10, which is able to reduce the later response against to olive pollen. These data are in agreement with the idea that several authors [ 92 , 93 ] propose, i.e., the prophylactic usefulness of T-cell vaccines. Figure 2 summarizes the potential of Ole e 1-derived T cell epitopes for their use as AIT.…”
Section: Ole E 1-peptidessupporting
confidence: 92%
“…They induce a regulatory response mediated by IL-35 and IL-10, which is able to reduce the later response against to olive pollen. These data are in agreement with the idea that several authors [ 92 , 93 ] propose, i.e., the prophylactic usefulness of T-cell vaccines. Figure 2 summarizes the potential of Ole e 1-derived T cell epitopes for their use as AIT.…”
Section: Ole E 1-peptidessupporting
confidence: 92%
“…To this end, the modification of allergens to reduce their reactivity with IgE, the use of safer routes of administration, and the incorporation of different adjuvants to slow allergen release and/ or stimulate a desired immune response have been considered. 7,8 In terms of safety, chemical modification of allergens (allergoids) can Methods: In a randomized, double-blind, double-dummy, placebo-controlled trial, 196 subjects received placebo or PM-HDM at 500, 1000, 3000, or 5000 mannanconjugated therapeutic units (mTU)/mL in 9-arm groups for 4 months. All subjects received 5 SC doses (0.5 ml each) every 30 days plus 0.2 ml SL daily.…”
Section: Introductionmentioning
confidence: 99%
“…Since Noon and Freeman's first description, 6 different ways to improve both safety and efficacy of AIT have been continuously sought. To this end, the modification of allergens to reduce their reactivity with IgE, the use of safer routes of administration, and the incorporation of different adjuvants to slow allergen release and/or stimulate a desired immune response have been considered 7,8 . In terms of safety, chemical modification of allergens (allergoids) can reduce their allergenicity while sublingual immunotherapy (SLIT) may be a safer alternative than subcutaneous immunotherapy (SCIT) 9 .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…While the use of AIT is well-established for the treatment of human allergies, its use as preventive immunotherapy in high-risk individuals has been proposed prior to sensitization [ 15 17 ]. Whether preventive AIT against IBH is feasible in horses remains to be established, and might become an interesting option to decrease the high incidence of IBH in horses exported from Iceland to continental Europe.…”
Section: Introductionmentioning
confidence: 99%